September 2009 Grants
Abrams, J., NIH, Universal Determinants of Alcohol-Induced Toxicity, $225,000; Adinoff, B., NIH, Clinical Trials Network: North Texas Node, $865,951; Adinoff, B., NIH, Clinical Trials Network: North Texas Node, $63,694 (supplement); Ariizumi, K., NIH, DC-HIL in Cutaneous Immunity, $250,000; Barton, T., HRSA, Ryan White Care Act Title IV Adolescent Initiative, $439,107.
Bathurst, I., NIH, Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria, $191,207; Baum, M., NIH, Effect of Prenatal Programming on Renal Tubular Transport, $216,000; Berry, J., NIH, Magnetic Resonance Imaging of Carotid Artery Subclinical Atherosclerosis, $122,010; Bharucha, K., NIH, Neuroendocrine Control of Energy Balance by the Drosophila AKH/Glucagon Receptor, $133,000; Bowers, D., NIH/St. Jude Children’s Research Hosp., Childhood Cancer Survivor Study, $2,786.
Brekken, R., NIH, Matricellular Proteins as Regulators of Tumor Progression, $200,138; Brown, M., NIH, Medical Scientist Training Program at UT Southwestern, $696,831; Chen, B., NASA, The Impact of HZE Particles on Adult Neural Stem Cells and Neurogenesis, $107,504; Chen, P., NIH, Epigenetic Gene Regulation by the Ocular Environment, $203,380 (supplement); Cui, W., DOD/UT Arlington, Temperature-Sensitive Polymer Magnetic Nanoparticle to Treat Prostate Cancer, $16,527.
De Brabander, J., NIH, Development of Small-Molecule Orexin-Receptor Agonists for Treating Narcolepsy, $293,797; Dries, D., NIH, Gamma-Secretase: The First Enzymology-Based Study of Intramembrane Proteolysis, $51,710; Dewey, R., NIH, Clinical Center for Neuroprotection in Parkinson Disease, $65,382; Dewey, R., NIH, Clinical Center for Neuroprotection in Parkinson Disease, $25,058; Eisch, A., NIH, Opiates and Adult Neurogenesis, $4,670 (supplement).
Elias, C., NIH, Role of Leptin-Mediated P13 Kinase Signaling on Reproductive Control, $207,499; Emslie, G., NIH/Univ.of Ala. at Birmingham, ATN Coordinating Center, $69,862; Evans, P., NIH/Wayne State Univ., Early Pharmacotheraphy Guided by Biomarkers in Autism, $38,184; Falck, J., NIH/New York Med. Coll., Hormonal Regulation of Blood Pressure, $49,883; Fontoura, B., NIH, Regulation of mRNA Export by Viral Proteins, $230,657.
Gabriel, V., NIH/Univ. of Pittsburgh, Rehabilitation Medicine Scientist Training Program, $100,000; Gardner, K., NIH, Molecular Biophysics Predoctoral Training Program, $113,047; Garner, H., NIH, Duplicate Article/Plagiarism Discovery, $81,534 (supplement); Gazdar, A., NIH, Novel Reagents and New Biomarkers for Lung Cancer, $195,860 (supplement); German, D., NIH, Novel Method for Alzheimer’s Disease Discovery, $167,663.
German, D., NIH/Robert Wood Johnson Med. Sch., Neuroprotective Activity of DJ-1 in Parkinson’s Disease, $20,566; Gibson, J. NIH, Cortical Circuit Changes and Mechanisms in a Mouse Model of Fragile X Syndrome, $69,662 (supplement); Hagan, K., NIH, Regulation of Memory CD4+ T Cell Responses by Type 1 Interferon, $28,188; Hamra, F., NIH, Biology of the ErbB Gene Family in Spermatogonial Development, $250,000; Hamra, F., NIH, Molecular Mechanisms of Spermatogonial Development, $207,502.
Hartono, J., NIH, Macrophages and TLR4 in Ischemic Acute Kidney Injury, $55,310; Hennes, H., HRSA, EMSC Targeted Issue Grants, $186,997; Herz, J., NIH, Enhancing Progranulin Expression: A Therapy for Frontotemporal Dementia, $400,000; Hill, J., NIH, Training in Cardiovascular Research, $853,373; Huang, C.L., NIH, Membrane Trafficking of Renal Potassium Channel; $208,250.
Huang, C.L., NIH, Membrane Trafficking of Renal Potassium Channel; $26,000 (supplement); Huber, K., NIH, Mechanisms of MGluR-Dependent Synaptic Plasticity, $69,662 (supplement); Huber, K., NIH, Study of Fragile X Mental Retardation Protein in Synaptic Function and Plasticity, $227,034; Huber, K., NIH, Study of Fragile X Mental Retardation Protein in Synaptic Function and Plasticity, $52,401 (supplement); Husain, M., NIH, Validating New NIH Clinical Tools in Parkinson’s Disease With/Without Depression, $318,297.
Igarashi, P., NIH, UT Southwestern O’Brien Kidney Research Core Center, $106,205 (supplement); Igarashi, P., NIH, Renal Control of Body Composition and Blood Pressure, $274,440; Igarashi, P., NIH, MicroRNA-Based Therapeutics for Rare Cystic Kidney Diseases, $322,411; Jiang, L., NIH, Regulation of Adenylyl Cyclase VII and Its Function in the Immune System, $36,831; Johnson, J., NIH, Genome-Wide Identification of PTF1-J Targets in Dorsal Neural Tube, $150,000.
Johnson, J., NIH, Regulation and Function of Asc1 (Mash1) in Neural Development, $80,000 (supplement); Joho, R., NIH, Role of Kv3-Type Potassium Channels in Alcohol Sensitivity, $125,000; Karandikar, N., NIH, Dissecting the Immune Basis of Disease and Therapy, $100,000 (supplement); Karandikar, N., NIH, Role of T Cells in the Immune Modulation of MS; $300,000 (supplement); Karandikar, N., NIH, Role of T Cells in the Immune Modulation of MS, $112,627 (supplement).
Karp, D., NIH, High Throughput Screening of the Autoimmune Epitome, $383,475; Kavalali, E., NIH, Role of SNARE Interactions in Central Synapse Function, $250,000; Kohler, J., NIH, Metabolic Incorporation of Photocrosslinking Sugars to Study Sialoside Function, $200,000; Kramer, H., NIH, Genetics of Endocytic Trafficking in the Eye, $135,595 (supplement); Kuro-o, M., NIH, Effects of Klotho Protein on Aging and Metabolism, $66,920 (supplement).
Lee, W., NIH, UT Southwestern Clinical Site for the Drug-Induced Liver Injury Network, $164,765; Lee, W., NIH, North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network, $256,910; Lee, W., NIH, A Multicenter Study of Acute Liver Failure in Adults, $684,688; Lee, W., NIH, A Multi-Center Study of Acute Liver Failure in Adults, $169,625 (supplement); Lemko, H., NIH, The Role of Ghrelin and NPY Signaling in the Regulation of Energy Homeostasis, $45,218.
Levine, Beth., NIH, Analysis of Beclin 1 in Autophagy and Tumor Suppression, $87,744 (supplement); Levine, Beth., NIH, Beclin 1 Bci-2 Interactions: Effects on Autophagy, $149,682; Levine, Benjamin, NIH, Aging Fitness and Failure: Mechanisms of Diastolic Dysfunction, $580,646; Levine, Benjamin, NIH, Aging Fitness and Failure: Mechanisms of Diastolic Dysfunction, $11,325 (supplement); Lin, F., NIH, Use of Umbilical Cord Blood-Derived HSC to Treat Acute Kidney Injury, $190,000.
Lin, F., NIH, Stem-Cell Therapy for Acute Kidney Injury, $240,000; Lin, R., NIH, Transcriptional Regulation by the Wnt Effector POP-1, $209,074; Liu, Q., NIH, Molecular Mechanism of Small RNA-Induced RNA Silencing, $80,000 (supplement); Liu, Y., NIH, Post-transcriptional Regulation of the Neurospora Circadian Clock, $201,250 (supplement); Lu, H., NIH, Cognition and Cerebrovascular Function Across the Lifespan, $116,338.
Lum, L., NIH, Chemical Disruption of the Hh and Wnt Pathways in Vertebrate Development, $150,000; Maalouf, N., NIH, Mentored Patient-Oriented Research Career Development, $107,840; Maher, E., NIH, Genotype and Metabolic Phenotype in Glioblastoma, $318,472; Malloy, C., NIH, Southwestern NMR Center for in Vivo Metabolism, $666,108; Malloy, C., NIH, Southwestern NMR Center for in Vivo Metabolism, $729,502 (supplement).
Mammen, P., NIH, Regulation of Tissue Hemoglobins in the Heart, $100,000; Martinez, E., NIH, Characterization of Small-Molecule Inhibitors of HDACs and DNMTs, $60,500 (supplement); McClung, C., NIH/Mount Sinai Sch. of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $45,000; McKnight, S., NIH, A Concerted Chemical, Biophysical and Molecular Biological Attack of Intracellular Pathways Relevant to Human Cancer, $2,166,630; McKnight, S., NIH/Univ. of Penn., Mechanisms of Signal Induced Alternative Splicing: CD45, $49,060.
Medin, P., NIH, Spinal Cord Tolerance to Radiosurgical Dose Delivery, $401,602 (supplement); Minna, J., NIH, UT SPORE in Lung Cancer, $1,903,506; Minna, J., UT M.D. Anderson, BATTLE-2 Correlative Studies, $25,000; Mohan, C., NIH, Foreboding Lupus Nephritis in Minority Women, $293,852; Mohan, C., Albert Einstein Coll. of Med. of Yeshiva Univ., Urine Biomarkers in Lupus Nephritis, $85,000.
Muallem, S., NIH, Hormone Regulation of (Ca2+) in Pancreatic Acinar Cells, $258,741; Muallem, S., NIH, Hormone Regulation of (Ca2+) in Pancreatic Acinar Cells, $76,825 (supplement); Muallem, S., NIH, Signaling Mechanisms in Salivary Gland Cells, $239,833; Muallem, S., NIH, Molecular Mechanisms of HCO3- Secretion by the Pancreatic Duct, $250,000; Niederkorn, J., NIH/Baylor Coll. of Med., Environmentally-Induced Ocular Surface Inflammation Mimicking Sjogren’s Syndrome, $30,000.
Norgard, M., NIH, Molecular Microbiology Training Grant, $250,650; Patel, V., NIH, Role of microRNA in Kidney Development and Pathogenesis of PKD, $134,773; Pertsemlidis, A., NIH, microRNA Regulation of Drug Sensitivity in Non-Small-Cell Lung Cancer, $13,342 (supplement); Pertsemlidis, A., NIH, microRNA Regulation of Drug Sensitivity in Non-Small- Cell Lung Cancer, $41,368 (supplement); Pertsemlidis, A., NIH, microRNA Regulation of Drug Sensitivity in Non-Small-Cell Lung Cancer, $144,787 (supplement).
Powell, C., NIH, Novel Genetic Animal Models of Autism, $175,000; Raskin, P., NIH/Case Western Reserve Univ., Epidemiology of Diabetes Interventions and Complications-Clinical Coordinating Center, $183,658; Ready, J., NIH, Catalytic Synthesis of Alpha-Branched Carbonyl Compounds, $159,294; Ready, J., NIH, Catalytic Synthesis of Alpha-Branched Carbonyl Compounds, $54,263 (supplement); Robertson, D., NIH, P63/IGFBP3/BCL2 Control of Corneal Epithelial Homeostasis, $200,000.
Roehrborn, C., NIH, Alternate Therapies for Benign Prostate Symptoms, $68,477; Rothermel, B., NIH, Calcineurin’s Role in Circadian Regulation of Cardiac Function and Remodeling, $250,000; Rutherford, C., NIH/UTHSC at Houston, Prevention of Complications of Bleeding Disorders Through Hemophilia Texas Centers, $31,053; Scherer, P., NIH, Dissecting Adipose Depot-Selective Regulation of Gene Programs, $397,571; Scheuermann, R., NIH/Northrop Grumman Info. Sys., Bioinformatics Resource Centers for Biodefense and Emerging/Re-emerging Infectious Diseases, $265,479.
Shaul, P., NIH, CRP, eNOS and Endothelial Dysfunction, $346,312; Shay, J., NIH, Cancer Biology Training Grant, $257,620; Siegelman, M., NIH, Regulation of Autoimmunity By CD44act Expressing T Cells, $250,000; Smith, D., NIH, Genetic Analysis of Olfaction, $212,500; Snell, W., NIH, Cell Surface Recognition and Cell Interactions, $242,500.
Snell, W., NIH, Cell Surface Recognition and Cell Interactions, $185,000 (supplement); Snell, W., NIH, Gamete Membrane Adhesion and Fusion During Fertilization, $175,000; Suel, G., NIH, Regulation of Pluripotent Differentiation by Gene Circuit Interactions, $200,000; Tamminga, C., NIH/Univ. of Md. Baltimore, Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes, $18,400; Toto, R., NIH, Mentoring Program for Clinical Researchers in Nephrology, $155,513.
Trivedi, M., NIH, A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care, $150,000; van Oers, N., NIH, microRNA Profiling of Pediatric Immunodeficiency Patients, $150,000; Vitetta, E., NIH, A Novel Vaccine to Prevent HCV Infection and Hence Liver Cancer, $471,638; White, M., NIH, Molecular Components Specifying Mucosal Cell Sensitivity to Influenza Infection, $125,000; White, M., NIH, Components of Ras-Mediated Growth Control, $26,137.
White, M., NIH, Components of Ras-Mediated Growth Control, $5,927 (supplement); White, M., NIH, Components of Ras-Mediated Growth Control, $6,250 (supplement); White, M., NIH, The RaLGTPase Regulatory Network, $152,000; White, M., NIH, The RaLGTPase Regulatory Network, $41,368 (supplement); Winkler, W., NIH, Regulation of Magnesium Homeostasis in Bacillus subtilis, $152,000.
Xiao, G., NIH, Secondary Data Analyses for Substance Abuse Research, $146,529; Xu, Y., NIH, Hypothalamic Mechanisms Mediating Estrogenic Regulation of Energy Homeostasis, $83,333; Yin, H., NIH, Phosphoinsitide Regulation of the Golgi, $287,284 (supplement); Yuan, J., NIH, Gating Mechanism of TRPCs and Orai1 by STIM1 and Their Role in Cardiac Hypertrophy, $82,120; Zimmern, P., NIH, Trial of Mid-Urethral Slings (TOMUS), $245,264.
German, D., Dallas Area Parkinsonism Soc., A Blood Biomarker for Parkinson’s Disease, $10,000; Huber, K., Simons Fndtn., Coordinated Control of Synapse Development by Autism Linked Genes, $300,000; Jiang, J., and Kramer, H., Welch Foundation, Protein Lipid Interactions in Endocytosis, $50,000.
Lee, J., American Heart Association, Structure of the Sterol Transporter ABCG5/G8 by Electron Microscopy, $7,778.05; Muallem, S., Machiah Fndtn., Machiah Foundation – Jewish Community Federation Program, $17,000; White, M., Leukemia and Lymphoma Soc., The Leukemia and Lymphoma Society Scholar, $43,650 (Pan, J., fellow).
Pharmaceutical studies, dollar amounts not available
Andersen, J., An Open-Label Safety and Efficacy Study of Study Drug for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-002; Chin, K., A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Event-Driven, Phase III Study to Assess the Effects of Study Drug on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension; Chin, K., Long-Term Single-Arm Open-Label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of Study Drug in Patients With Symptomatic Pulmonary Arterial Hypertension; Chin, K., A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Dose-Response of Study Drug on Acute Hemodynamics in Subjects With Idiopathic and Familial Pulmonary Arterial Hypertension.
Dowell, J., A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Study Drug and Celecoxib (Celebrex) versus Study Drug/Placebo in Advanced Non-Small-Cell Lung Cancer Patients; Gupta, S., The SWIFT Study: A Prospective, Randomized, Open-Label, Phase IV Study to Evaluate the Rationale of Switching From Fixed-Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed-Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Regimen; He, Y., An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Study Drug in Subjects With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration or Macular Edema Secondary to Retinal Vein Occlusions Who Have Completed a Genentech-Sponsored Study Drug Study.
Szmuk, P., Use of VeinViewer for Insertion of Peripheral Venous Cannula in Pediatric Patients With Difficult Intravenous Access; Wait, M., A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Study Vaccine in Adult Patients Scheduled for Cardiothoracic Surgery.